Becton Dickinson Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Becton Dickinson kazanç ve gelirin sırasıyla yıllık 15.9% ve 5.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 15.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 16.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

16.0%

Kazanç büyüme oranı

15.1%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	0%
Gelir büyüme oranı	5.5%
Gelecekteki özkaynak getirisi	16.8%
Analist kapsamı	Good
Son güncelleme	25 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BMV:BDX * - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2027	23,629	2,835	N/A	6,002	3
9/30/2026	22,794	2,662	3,465	4,888	12
9/30/2025	21,774	2,432	4,206	4,895	16
9/30/2024	20,171	2,003	3,028	4,486	15
6/30/2024	19,828	1,459	3,221	3,944	N/A
3/31/2024	19,716	1,364	3,025	3,760	N/A
12/31/2023	19,492	1,265	2,649	3,431	N/A
9/30/2023	19,372	1,470	2,115	2,989	N/A
6/30/2023	19,046	1,582	1,743	2,638	N/A
3/31/2023	18,809	1,556	1,009	1,966	N/A
12/31/2022	18,738	1,486	1,361	2,359	N/A
9/30/2022	18,870	1,545	1,661	2,634	N/A
6/30/2022	18,958	1,412	1,465	2,575	N/A
3/31/2022	18,924	1,430	2,041	3,141	N/A
12/31/2021	18,534	1,079	2,620	3,751	N/A
9/30/2021	19,131	1,514	3,453	4,647	N/A
6/30/2021	19,066	1,486	4,222	5,177	N/A
3/31/2021	18,313	1,379	4,150	5,064	N/A
12/31/2020	18,207	1,507	3,476	4,359	N/A
9/30/2020	16,074	245	2,728	3,497	N/A
6/30/2020	16,917	786	2,474	3,429	N/A
3/31/2020	17,414	923	2,509	3,499	N/A
12/31/2019	17,355	760	2,835	3,798	N/A
9/30/2019	17,290	1,081	2,373	3,330	N/A
6/30/2019	17,108	784	2,359	3,265	N/A
3/31/2019	17,036	926	2,009	2,875	N/A
12/31/2018	17,063	894	1,906	2,790	N/A
9/30/2018	15,983	159	1,970	2,865	N/A
6/30/2018	14,747	621	1,837	2,685	N/A
3/31/2018	13,503	-99	N/A	2,527	N/A
12/31/2017	12,251	294	N/A	2,555	N/A
9/30/2017	12,093	1,030	N/A	2,550	N/A
6/30/2017	12,158	759	N/A	2,129	N/A
3/31/2017	12,321	1,314	N/A	2,579	N/A
12/31/2016	12,419	1,309	N/A	2,411	N/A
9/30/2016	12,483	976	N/A	2,559	N/A
6/30/2016	12,312	1,139	N/A	2,532	N/A
3/31/2016	12,234	810	N/A	2,236	N/A
12/31/2015	11,217	688	N/A	1,907	N/A
9/30/2015	10,282	695	N/A	1,730	N/A
6/30/2015	9,410	815	N/A	1,591	N/A
3/31/2015	8,448	1,079	N/A	1,492	N/A
12/31/2014	8,468	1,150	N/A	1,677	N/A
9/30/2014	8,446	1,185	N/A	1,746	N/A
6/30/2014	8,345	974	N/A	1,876	N/A
3/31/2014	8,239	941	N/A	1,830	N/A
12/31/2013	8,169	930	N/A	1,626	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BDX * 'nin tahmini kazanç büyümesi (yıllık 15.9% ) tasarruf oranının ( 7.9% ) üzerindedir.

Kazançlar ve Piyasa: BDX * şirketinin kazançlarının (yıllık 15.9% ) MX pazarından (yıllık 11.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: BDX * şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: BDX * şirketinin gelirinin (yıllık 5.4% ) MX pazarından (yıllık 7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BDX * şirketinin gelirinin (yıllık 5.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BDX * 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 16.8 %).

Becton Dickinson Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Recent updates

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Upcoming dividend of US$0.95 per share

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Third quarter 2024 earnings released: EPS: US$1.68 (vs US$1.37 in 3Q 2023)

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Second quarter dividend of US$0.95 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024

Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024

BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool

Senior VP recently sold Mex$1.3m worth of stock

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Upcoming dividend of US$0.95 per share

Insider recently sold Mex$13m worth of stock

Second quarter dividend of US$0.95 announced

Second quarter dividend of US$0.95 announced

Second quarter 2024 earnings released: EPS: US$1.86 (vs US$1.54 in 2Q 2023)

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Insider recently sold Mex$6.8m worth of stock

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Senior VP recently sold Mex$1.1m worth of stock

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Upcoming dividend of US$0.95 per share

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

First quarter dividend of US$0.95 announced

First quarter 2024 earnings released: EPS: US$0.97 (vs US$1.71 in 1Q 2023)

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Fourth quarter dividend of US$0.95 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Insider recently sold Mex$5.0m worth of stock

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Insider recently sold Mex$2.2m worth of stock

Board Member recently sold Mex$4.0m worth of stock

Insider recently sold Mex$6.2m worth of stock

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: EPS: US$1.37 (vs US$1.29 in 3Q 2022)

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Upcoming dividend of US$0.91 per share at 1.5% yield

Second quarter 2023 earnings released

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Upcoming dividend of US$0.91 per share at 1.6% yield

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

First quarter 2023 earnings released: EPS: US$1.71 (vs US$2.30 in 1Q 2022)

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Upcoming dividend of US$0.91 per share

Full year 2022 earnings released: EPS: US$5.42 (vs US$6.92 in FY 2021)